Aflac AFL Cancer — Effect of changes in discount rate assumptions
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aflac in its filing.
Tagged under the XBRL concept us-gaap:AociLiabilityForFuturePolicyBenefitExpectedNetPremiumBeforeTax.
The official record: Aflac’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aflac's cancer — effect of changes in discount rate assumptions.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aflac's cancer — effect of changes in discount rate assumptions?
- Aflac (AFL) reported cancer — effect of changes in discount rate assumptions of -$1.25B in Q1 2026.
- How has Aflac's cancer — effect of changes in discount rate assumptions changed year-over-year?
- Aflac's cancer — effect of changes in discount rate assumptions decreased by 363.7% year-over-year, from -$270M to -$1.25B.
- What is the long-term trend for Aflac's cancer — effect of changes in discount rate assumptions?
- Over 2 years (2023 to 2025), Aflac's cancer — effect of changes in discount rate assumptions has grown at a -30.1% compound annual growth rate (CAGR), from $5B to -$2.44B.
- What does cancer — effect of changes in discount rate assumptions mean?
- The financial impact resulting from changes in the discount rates used to calculate the present value of future policy benefits for the cancer segment. This reflects the sensitivity of long-term liabilities to interest rate environments.